Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6058574 | 0.90 | TDP1 (0.42) | BACE1MAPTALDH1A1POLBABCB1 | |
| SCHEMBL5528639 | 0.90 | BACE1 (0.38) | BACE1MAPTALDH1A1POLBABCB1 | |
| SCHEMBL27815805 | 0.81 | GPR35 (0.52) | MAPTALDH1A1POLBMEN1KMT2A | |
| SCHEMBL6058698 | 0.80 | BACE1 (0.34) | BACE1MAPTALDH1A1POLBABCB1 | |
| SCHEMBL27376059 | 0.77 | GPR35 (0.57) | MAPTALDH1A1CRHBPCRHR2MEN1 | |
| SCHEMBL6701790 | 0.76 | ESR1 (0.46) | ESR1ESR2GAA | |
| SCHEMBL9812448 | 0.76 | GPR35 (0.57) | MAPTALDH1A1CRHBPCRHR2MEN1 | |
| SCHEMBL6910913 | 0.75 | MAPT (0.51) | BACE1MAPTALDH1A1POLBABCB1 | |
| SCHEMBL8214082 | 0.72 | ALDH1A1 (0.44) | MAPTALDH1A1POLBMAPK1ACHE | |
| SCHEMBL27330816 | 0.72 | CTSB (0.49) | MAPTALDH1A1ESR1ESR2CRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0877607-B1 | BIPHENYL COMPOUNDS AND USE THEREOF AS OESTROGENIC AGENTS | AVENTIS PHARMA SA (FR) | 2006-11-15 | — | — | EP | claimed |
| US-6794415-B2 | Biphenyl compounds and their use as oestrogenic agents | AVENTIS PHARMA S.A. (FR) | 2004-09-21 | — | — | US | claimed |
| US-20040043993-A1 | Biphenyl compounds and their use as oestrogenic agents | AVENTIS PHARMA S.A. | 2004-03-04 | — | — | US | claimed |
| US-20020068736-A1 | Biphenyl compounds and their use as oestrogenic agents | LESUISSE DOMINIQUE (FR) | 2002-06-06 | — | — | US | claimed |
| US-6288126-B1 | Biphenyl compounds and use thereof as oestrogenic agents | AVENTIS PHARMA S.A. | 2001-09-11 | — | — | US | claimed |
| EP-0877607-B1 | BIPHENYL COMPOUNDS AND USE THEREOF AS OESTROGENIC AGENTS | AVENTIS PHARMA SA (FR) | 2006-11-15 | — | — | EP | disclosed |
| US-6794415-B2 | Biphenyl compounds and their use as oestrogenic agents | AVENTIS PHARMA S.A. (FR) | 2004-09-21 | — | — | US | disclosed |
| US-20040043993-A1 | Biphenyl compounds and their use as oestrogenic agents | AVENTIS PHARMA S.A. | 2004-03-04 | — | — | US | disclosed |
| US-6563008-B2 | Treatment of disorders linked to hypofolliculinemia and of certain estrogen-dependent pathologies such as prostatic adenomas or carcinomas, and of benign tumours of the breast | AVENTIS PHARMA S.A. (FR) | 2003-05-13 | — | — | US | disclosed |
| US-20020068736-A1 | Biphenyl compounds and their use as oestrogenic agents | LESUISSE DOMINIQUE (FR) | 2002-06-06 | — | — | US | disclosed |
| US-6288126-B1 | Biphenyl compounds and use thereof as oestrogenic agents | AVENTIS PHARMA S.A. | 2001-09-11 | — | — | US | disclosed |
| EP-0877607-A1 | BIPHENYL COMPOUNDS AND USE THEREOF AS OESTROGENIC AGENTS | HOECHST MARION ROUSSEL (FR) | 1998-11-18 | — | — | EP | disclosed |
| WO-1997027846-A1 | BIPHENYL COMPOUNDS AND USE THEREOF AS OESTROGENIC AGENTS | HOECHST MARION ROUSSEL (FR) | 1997-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068736-A1 | Biphenyl compounds and their use as oestrogenic agents | ESR2, ESR1, CYP19A1 | BACE1 1661/4885MAPT 4496/4885ALDH1A1 381/4885 |
| US-20040043993-A1 | Biphenyl compounds and their use as oestrogenic agents | CYP19A1, HSD17B11, GPER1 | BACE1 677/4885MAPT 4418/4885ALDH1A1 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.